Patrick Lamy - 10 Jan 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting relationship: Senior Vice President, Commercial Strategy
Issuer ticker: AKRO
Reported as of: 10 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jan 2023, 18:51:36 UTC
Next SEC filing: 12 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Young, attorney-in-fact

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 11 Jan 2023.

Key facts

This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jan 2023, 18:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKRO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: -100,000
Change %: -50%
Price: $0.000000
Shares after: 100,000
Date: 10 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $44.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on January 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC remarks

Senior Vice President, Commercial Strategy